At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
Atorvastatin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating Atorvastatin, Pravastatin, and 2 other interventions for Rheumatoid Arthritis. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates using phenotypic probes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsLakefront Biotherapeutics NV
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionJan 2021
TodayJul 2026
First PostedOct 29, 2020
Enrollment StartNov 4, 2020
Primary CompletionJan 13, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.7 years ago
Interventions
Atorvastatindrug
Administered as single dose tablet orally.
Pravastatindrug
Administered as single dose tablet orally.
Rosuvastatindrug
Administered as single dose tablet orally.
Filgotinibdrug
Administered as tablet orally once daily for 11 days.